3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
28
Phase 2
23
Phase NA
3
Phase 1
3
Phase 1/2
2
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
15
Lymphoid
15
Sarcoma
2
Gynecologic
2
Genitourinary
2
Myeloid
1
Classical hematology
1
Breast
1
Conditions
Breast Neoplasms
1
Interventions
Capecitabine
17
Paclitaxel
16
Docetaxel
13
Carboplatin
12
Cyclophosphamide
11
Gemcitabine
9
Epirubicin
9
Trastuzumab
8
Letrozole
8
Doxorubicin
7
pertuzumab
5
Cisplatin
5
Vinorelbine
4
130-nm albumin-bound paclitaxel
4
exemestane
3
Zoledronic Acid
3
Tamoxifen
3
Neoadjuvant Therapy
3
Lapatinib
3
Injections
3
Drug Therapy
3
Ado-Trastuzumab Emtansine
3
AC protocol
3
pyrotinib
2
palbociclib
2
camrelizumab
2
apatinib
2
Thiotepa
2
Taxes
2
Standard of Care
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Methotrexate
×
Breast
×
Clear all
NCT01204437
2016-02-10
ICE-II
GBG Forschungs GmbH
Phase 2/3
Completed
400 enrolled